Cara Therapeutics (CARA) Debt/EBITDA US GAAP (year values) |
|||||||||
2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
Debt/EBITDA | -31.4 | 1.85 | 1.71 | 0.47 | 0.49 | 0.43 | |||
Changes by years, y/y, % | -2 423% | -106% | -8% | -72% | +3% | -25.2% |
Cara Therapeutics. Debt/EBITDA
Cara Therapeutics. Debt/EBITDA, changes, %
Cara Therapeutics (CARA) Debt/EBITDA US GAAP (quarter values) |
||||||||
2023Q4 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
Debt/EBITDA | 0.48 | 0.49 | 0.20 | 0.46 | 0.43 | 0.43 | ||
Changes by years, y/y, % | -71% | -70% | -84% | -44% | -27% | |||
Changes by quarters, q/q, % | -20% | +2% | -58% | +126% | -5% |